Comparison of the oncolytic activity of a replication‐competent and a replication‐deficient herpes simplex virus 1

URN to cite this document:: urn:nbn:de:bvb:355-epub-578826
DOI to cite this document:: 10.5283/epub.57882

Lindner, Georg ; Walter, Annika ; Magnus, Clara L. ; Rosenhammer, Katharina ; Holoborodko, Bohdan ; Koch, Victoria ; Hirsch, Sarah ; Grossmann, Luis ; Li, Suqi ; Knipe, David M. ; DeLuca, Neal ; Schuler‐Thurner, Beatrice ; Gross, Stefanie ; Schwertner, Barbara ; Toelge, Martina ; Rohrhofer, Anette ; Stöckl, Sabine ; Bauer, Richard J. ; Knoll, Gertrud ; Ehrenschwender, Martin ; Haferkamp, Sebastian ; Schmidt, Barbara

; Schuster, Philipp

License: Creative Commons Attribution Non-commercial No Derivatives 4.0
PDF
Early View
(3MB)

Date of publication of this fulltext: 12 Mar 2024 07:12

Alternative links to fulltext:DOI Publisher

This publication is part of the DEAL contract with Wiley.

Details

Preview: Early View

Export bibliographical data

Abstract

In 2015, the oncolytic herpes simplex virus 1 (HSV-1) T-VEC (talimogene laherparepvec) was approved for intratumoral injection in non-resectable malignant melanoma. To determine whether viral replication is required for oncolytic activity, we compared replication-deficient HSV-1 d106S with replication-competent T-VEC. High infectious doses of HSV-1 d106S killed melanoma (n = 10), head-and-neck ...